A Novel Dual-Cab Nectin-4 X CD3 Bispecific Antibody Targeting Solid Tumors
Conditionally Active Biologics Eliminate Senescence Cells in Cancer and Aging
Novel Conditionally Active Bispecific HER2 X CD3 T-Cell Engager Targeting Solid Tumors
NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety
NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety
A Phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL antibody drug conjugate
Protein-associated Chemical Switches Differentially Modulate the Binding Activities of Human Apolipoprotein E Isoforms with Their Receptors and with Amyloid Beta Peptides.
Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors
Novel Conditionally Active Bispecific EpCAM x CD3 T Cell Engagers Targeting Solid Tumors
Novel conditionally active ADCs (CAB ADCs): A novel class of molecules targeting solid tumors
